Skip Navigation



British Medical Bulletin Advance Access published online on April 18, 2007
British Medical Bulletin, doi:10.1093/bmb/ldm008
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
81-82/1/115    most recent
ldm008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fletcher, S.
Right arrow Articles by Bain, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fletcher, S.
Right arrow Articles by Bain, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Eosinophilic leukaemia

Sarah Fletcher and Barbara Bain*

Department of Haematology, St. Mary's Hospital Campus of Imperial College, Praed Street, London W2 1NY, UK

* Correspondence to: Professor Barbara Bain Department of Haematology St Mary's Hospital, Praed Street London W2 1NY, UK. E-mail: b.bain{at}imperial.ac.uk

The last few years have seen much progress in our understanding of, and treatments for, eosinophilic leukaemia. In preparing this review, we used Pubmed and the archives of well-known Haematology journals to search for relevant research papers and reviews published in the last 5–10 years. In this article, we review the differential diagnosis and sub-classification of eosinophilic leukaemia, and go on to discuss clinical features, investigation and treatment of these disorders. We are increasingly able to classify clonal eosinophilias based on the underlying molecular genetic abnormalities, and prognosticate and treat patients according to this. The successful treatment of certain of these patients with imatinib, followed by a greater understanding of the mechanism of this treatment, has revolutionized the outlook for many patients with eosinophilic leukaemia. New similar tyrosine kinase inhibitors and other promising therapies are on the horizon.

Keywords: Eosinophilic • leukaemia • eosinophilia

Accepted for publication February 27, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.